Traumatic brain injuries are a major public health concern globally. Diagnosis is based on computed tomography, however, injuries are not always visible in these scans. Recent studies support the use of glial fibrillary acidic protein (GFAP) test to help evaluating the need for a CT scan in case traumatic brain injury or concussion is suspected.
Figure 1. SDS-PAGE of recombinant GFAP fragment under reducing conditions in a gradient gel (4-20%). 2.5 μg of purified protein was loaded on the gel.
We have now developed a recombinant GFAP protein that can be used as a standard or calibrator in GFAP immunoassay development. With the recent launch of several anti-GFAP antibodies, we now can provide all key reagents for assay development.